BRAF V600E Mutation Detection in Circulating Cell-Free DNA by Digital Droplet PCR

Casandra

Casandra Test Code AR78044Version 1 (DRAFT)

Performing Lab

Lab ARUP LaboratoriesLab Test ID 2013921CPT Code 81210

BRAF V600E Mutation Detection in Circulating Cell-Free DNA by Digital Droplet PCR

Also known as: BRAF CFDNA

Clinical Use

Order Test

Use

Determining BRAF mutation status is useful in identifying patient eligibility for therapy with kinase inhibitors. The oncogenic BRAF c.1799T>A, p.Val600Glu (V600E) mutation is associated with a clinical response to the BRAF inhibitors dabrafenib and vemurafenib and the MEK inhibitors trametinib and cobimetinib in some tumor types. Monitoring BRAF V600E mutation assists in selecting candidates for targeted therapy and assessing response to therapy and disease progression.

Special Instructions

Specimens must be collected using the Cell-Free DNA Blood Collection Tube available via eSupply using ARUP Connect(TM) or contact ARUP Client Services. Transport should be in cfDNA BCT tubes. Specimen kit can be ordered from ARUP Supply #52358.

Limitations

Other variants at the BRAF V600 codon (V600K, V600R) will not be detected. Mutations in other locations within the BRAF gene or in other genes will not be detected. Limit of detection is dependent on the amplifiable cell-free DNA extracted from plasma, ranging from 0.5 percent to below 0.01 percent mutant allele frequency. Results must be interpreted within the clinical context and other relevant data should not be used alone for the diagnosis of malignancy.

Test Details

New York Approved